Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade C 64.65 -6.36% -4.39
RARE closed down 6.36 percent on Friday, March 22, 2019, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical RARE trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 BB Squeeze Started Range Contraction 0.00%
Mar 21 Multiple of Ten Bearish Other -6.36%
Mar 21 Overbought Stochastic Strength -6.36%
Mar 20 Outside Day Range Expansion -5.00%
Mar 20 Overbought Stochastic Strength -5.00%
Mar 19 MACD Bearish Signal Line Cross Bearish -5.52%
Mar 19 NR7 Range Contraction -5.52%

Older signals for RARE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Rare Diseases Enzyme Replacement Therapy Biologics Rare And Ultra Rare Diseases
Is RARE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 90.98
52 Week Low 37.44
Average Volume 638,552
200-Day Moving Average 65.7665
50-Day Moving Average 57.6978
20-Day Moving Average 65.637
10-Day Moving Average 67.187
Average True Range 3.0187
ADX 47.24
+DI 26.3389
-DI 13.6432
Chandelier Exit (Long, 3 ATRs ) 61.29389999999999
Chandelier Exit (Short, 3 ATRs ) 65.2561
Upper Bollinger Band 70.1395
Lower Bollinger Band 61.1345
Percent B (%b) 0.39
BandWidth 13.719396
MACD Line 2.8829
MACD Signal Line 3.2757
MACD Histogram -0.3928
Fundamentals Value
Market Cap 2.75 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -9.59
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 71.13
Resistance 3 (R3) 71.82 70.35 70.05
Resistance 2 (R2) 70.35 68.70 70.01 69.69
Resistance 1 (R1) 67.50 67.68 66.77 66.81 69.33
Pivot Point 66.03 66.03 65.66 65.69 66.03
Support 1 (S1) 63.18 64.38 62.45 62.49 59.97
Support 2 (S2) 61.71 63.36 61.37 59.61
Support 3 (S3) 58.86 61.71 59.25
Support 4 (S4) 58.17